Drug Profile
Research programme: cytomegalovirus infection antivirals - INAGEN
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator INAGEN
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Denmark
- 18 Dec 2008 Preclinical trials in Cytomegalovirus infections in Denmark (unspecified route)